Huntsman Corporation in its pending $300 million acquisition of CVC Thermoset Specialties.
Huntsman Corporation in its $350 million acquisition of Icynene-Lapolla.
Bristol-Myers Squibb in its $13.4 billion divesture of Celgene’s OTEZLA® program to Amgen in connection with Bristol-Myers Squibb’s $90 billion acquisition of Celgene.
Huntsman Corporation in its $2.1 billion sale of its chemical intermediates and surfactants businesses to Indorama Ventures.
Fortive Corporation in Industrial Scientific’s $570 million acquisition of Intelex Technologies.
Huntsman Corporation in its $750 million senior notes offering.
